Diagnostic value of the PPI test for detection of GERD in Korean patients and factors associated with PPI responsiveness

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 5, 2010, Pages 533-539

  Cho, Yu Kyung ^a   Choi, Myung Gyu ^a   Lim, Chul Hyun ^a   Nam, Kwan Woo ^a   Chang, Jae Hyuck ^a   Park, Jae Myung ^a   Lee, In Seok ^a   Kim, Sang Woo ^a   Choi, Kyu Yong ^a   Chung, In Sik ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Esophagitis; Gastroesophageal reflux disease; Proton pump inhibitors

Indexed keywords

LANSOPRAZOLE;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESPONSE; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; QUALITY OF LIFE; REFLUX ESOPHAGITIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; CHI-SQUARE DISTRIBUTION; ESOPHAGEAL PH MONITORING; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; KOREA; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 77951689544     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521003650172     Document Type: Article

References (19)

1. Tytgat GN, McColl K, Tack J, Holtmann G, Hunt RH, Malfertheiner P, et al. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008;27:249-256
2. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroe-sophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004;140:518-527
3. Gasiorowska A, Fass R. The proton pump inhibitor (PPI) test in GERD: does it still have a role? J Clin Gastroenterol 2008;42:867-874
4. Fock KM, Talley NJ, Fass R, Goh KL, Katelaris P, Hunt R, et al. Asia-Pacific consensus on the management of gastro-esophageal reflux disease: update. J Gastroenterol Hepatol 2008;23:8-22. (Pubitemid 350265214)
5. Xia HH, Lai KC, Lam SK, Hu WH, Wong NY, Hui WM, et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Aliment Pharmacol Ther 2003;17:369-377
6. Lee KJ, Kwon HC, Cheong JY, Cho SW. Demographic, Clinical, and Psychological Characteristics of the Heartburn Groups Classified Using the Rome III Criteria and Factors Associated with the Responsiveness to Proton Pump Inhibitors in the Gastroesophageal Reflux Disease Group. Digestion 2009;79:131-136
7. Wu JC, Chan FK, Ching JY, Leung WK, Lee YT, Sung JJ. Empirical treatment based on 'typical' reflux symptoms is appropriate in a population with a high prevalence of Helicobacter pylori infection. Gastrointest Endosc 2002;55: 461-465
8. Lee ES, Kim N, Lee SH, Park YS, Kim JW, Jeong SH, et al. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive esophagitis and non-erosive reflux disease. Aliment Pharmacol Ther 2009;30:154-164
9. Sinn DH, Kim JH, Kim S, Son HJ, Kim JJ, Rhee JC, Rhee PL. Response rate and predictors of response in a short-term empirical trial of high-dose rabeprazole in patients with globus. Aliment Pharmacol Ther 2008;27:1275-1281 (Pubitemid 351697271)
10. Wenner J, Johnsson F, Johansson J, Oberg1 S. Wireless oesophageal pH monitoring: feasibility, safety and normal values in healthy subjects. Scand J Gastroenterol 2005;40:768-774 (Pubitemid 40978851)
11. Weusten BL, Roelofs JM, Akkermans LM, Van Berge-Henegouwen GP, Smout AJ. The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology 1994;107:1741-1745
12. Sewitch MJ, Abrahamowicz M, Bitton A, Daly D, Wild GE, Cohen A, et al. Psychological distress, social support, and disease activity in patients with inflammatory bowel disease. Am J Gastro-enterol 2001;96:1470-1479 (Pubitemid 32455077)
13. Modlin IM, Hunt RH, Malfertheiner P, Moayyedi P, Quigley EM, Tytgat GN, et al. Non-erosive reflux disease-defining the entity and delineating the management. Digestion 2008;78(Suppl 1):1-5.
14. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004;2:656-664 (Pubitemid 39013424)
15. Ahlawat SK, Novak DJ, Williams DC, Maher KA, Barton F, Benjamin SB. Day-to-day variability in acid reflux patterns using the BRAVO pH monitoring system. J Clin Gastroen-terol 2006;40:20-24 (Pubitemid 44378072)
16. Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux-the "sensitive oesophagus". Gut 1997;40:587-590
17. Aanen MC, Weusten BL, Numans ME, de Wit NJ, Baron A, Smout AJ. Diagnostic value of the proton pump inhibitor test for gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther 2006;24:1377-1384 (Pubitemid 44571568)
18. Taghavi SA, Ghasedi M, Saberi-Firoozi M, et al. Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole. Gut 2005;54: 1067-1071 (Pubitemid 41025896)
19. Bradley LA, Richter JE, Pulliam TJ, Haile JM, Scarinci IC, Schan CA, et al. The relationship between stress and symptoms of gastroesophageal reflux: the influence of psychological factors. Am J Gastroenterol 1993;88:11-19.